Sensyne enters health data partnership with US-based OMNY

Clinical artificial intelligence (AI) company Sensyne Health announced a new strategic relationship with US-based data network company OMNY Health on Friday.

The AIM-traded firm said the arrangement would establish a framework under which Sensyne could contract for access to OMNY Health's platform of more than 22 million de-identified patient records across all therapeutic areas.

That would support Sensyne's data analytics work for life science companies.

Additionally, Sensyne and OMNY agreed to work together on commercial projects for life science clients, to “advance and accelerate” ethical medical research.

Sensyne said that by bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies and their health system partners would have more opportunities to support life sciences research.

The company said the OMNY data network complemented its existing global medical research dataset of 22.1 million patients, sourced through strategic partnerships with US health systems and the UK's NHS trusts.

“This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries,” said Sensyne’s North America president Derek Baird.

“The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.

“We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients.”

At 1424 BST, shares in Sensyne Health were up 0.93% at 109p.